ARCHIVES

ODAC votes 9-6 in favor of Clolar for pediatric acute lymphoblastic leukemia, but votes against Marqibo for non-Hodgkin’s lymphoma.

This article is from The Cancer Letter archive.

Vol. 30 No. 46 | December 10, 2004

Download PDF Visit The Full Archive

Related Articles

President’s Budget Versus NCI’s Bypass: A Comparison

February 21, 1992

NCAB, Hammer Agree On how 41 Billion To Be Handled: No String Attached

October 14, 1988

Aranesp Approval Introduces Competition To $1.8 Billion U.S. Cancer Anemia Market

August 2, 2002

Smaller Ultrasound-Guided Biopsy Needle Safe, Effective, For Suspected Breast Cancer

May 30, 2003

Pregnancy-Associated Breast Cancer More Likely Diagnosed At Advanced Stage

February 27, 2009

Adamson Is Named Acting Deputy; Broder Begins Search For Roper Replacement

May 25, 1990